Carcinoid
A Comprehensive Review

References

• Lubarsh O. Uber den pimaeren krebs des ileum nebst Bemerkungen ueber das gleichzeitige Vorkommen von krebs und Tuberculos. Virchows Arch 1888; 11: 280–317.
   Google Scholar
• Ranson WB. Case of primary carcinoma of ileum. Lancet 1890; 2: 1020.
   Google Scholar
• Obendorfer S. Karzinoide Rumoren des Dunndarms. Frankf Z Pathol 1907; 1: 425–9.
   Google Scholar
• Masson P. Carcinoids (argentaffin-cell tumors) and nerve hyperplasia of appendicular mucosa. Am J Pathol 1928; 4: 181–212.
   PubMedGoogle Scholar
• Gerstle JT, Kauffman Jr. GL, Koltun WA. The incidence, management, and outcome of patients with gastrointestinal carcinoids and second primary malignancies. J Am Coll Surg 1995; 180: 427–32.
   PubMed Web of Science ®Google Scholar
• Lembech F. 5-hydroxytryptamine in carcinoid tumor. Nature 1953; 172: 910–1.
   Web of Science ®Google Scholar
• Page I, Corcoran A, Vollenfrend S. Argentaffinoma as an endocrine tumor. Lancet 1955; 1: 198–9.
   Google Scholar
• Modlin IM, Sandor A. An analysis of 8 305 cases of carcinoid tumors. Cancer 1997; 79: 813–29.
   PubMed Web of Science ®Google Scholar
• Woods HF, Bax ND, Ainsworth I. Abdominal carcinoid tumours in Sheffield. Digestion 1990; 45(Suppl 1): 17–22.
   Google Scholar
• Newton JN, Swerdlow AJ, dos Santos Silva IM, et al. The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer 1994; 70: 939–42.
   Google Scholar
• Lu Cortez L, Clemente C, Puig V, Mirada A. Carcinoid tumor. An analysis of 131 cases. Rev Clin Esp 1994; 194: 291–3.
   PubMed Web of Science ®Google Scholar
• Soga J. Carcinoids of the rectum: An evaluation of 1 271 reported cases. Surg Today 1997; 27: 112–9.
   PubMed Web of Science ®Google Scholar
• Soga J. Carcinoids of the small intestine: A statistical evaluation of 1 102 cases collected from the literature. J Exp Clin Cancer Res 1997; 16: 353–63.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Sauer WG, Docherty MB, Baggenstoss AH. Life history of the carcinoid tumor of the small intestine. Cancer 1961; 14: 291–3.
   Web of Science ®Google Scholar
• Berge T, Linell F. Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand [A] 1976; 84: 322–30.
   PubMedGoogle Scholar
• Neary PC, Redmond PH, Houghton T, Watson GR, Bouch-ier-Hayes D. Carcinoid disease: review of the literature. Dis Colon Rectum 1997; 40: 349–62.
   PubMed Web of Science ®Google Scholar
• Moertel CG. Kamofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987; 5: 1502–22.
   PubMedGoogle Scholar
• Jensen R, Norton J. Carcinoid tumors and the carcinoid syndrome. In: DeVita VT, Hellman S, Rosenberg A, eds. Principles and practice of oncology, 5th ed.. Philadelphia: JB Lippincott Co; 1996. p. 1704–23.
   Google Scholar
• Scully R, Eugene M, McNeely W, Ebeling S, Phillips L. Case 9-1997. N Engl J Med 1997; 336: 861–7.
   Google Scholar
• Nilsson O. Gastrointestinal carcinoids-aspects of diagnosis and classification. APMIS 1996; 104: 481–92.
   PubMed Web of Science ®Google Scholar
• Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988; 41: 185–200.
   PubMed Web of Science ®Google Scholar
• Ahlman H. Gut neuroendocrine tumours. Wiad Lek 1997; 50((Suppl Pt 1)): 4–9.
   Google Scholar
• Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999; 340: 858–68.
   PubMed Web of Science ®Google Scholar
• Modlin IM, Sandor A, Tang LH, Kidd M, Zelterman D. A 40-year analysis of 265 gastric carcinoids. Am J Gastroenterol 1997; 92: 633–8.
   PubMed Web of Science ®Google Scholar
• Modlin IM, Tang LH. The gastric enterochromaffin-like cell: an enigmatic cellular link. Gastroenterology 1996; 111: 783–810.
   PubMed Web of Science ®Google Scholar
• Rindi G, Luinetti O, Comaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastro-enterology 1993; 104: 994–1006.
   Google Scholar
• Thomas RM, Baybick JH, Elsayed AM, Sobin LH. Gastric carcinoids. An immunohistochemical and clinicopathologic study of 104 patients. Cancer 1994; 73: 2053–8.
   Google Scholar
• Gough DB, Thompson GB, Crotty TB, et al. Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia. World J Surg 1994; 18: 473–9 (discus-sion 479-80).
   PubMed Web of Science ®Google Scholar
• Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 1979; 2: 327–34.
   PubMedGoogle Scholar
• Sundler F. Pathogenesis and diagnosis of enterochromaffin-like cell tumors. Ann NY Acad Sci 1994; 733: 24–35.
   PubMed Web of Science ®Google Scholar
• Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1983; 1: 727–40.
   PubMed Web of Science ®Google Scholar
• Feldman JM. Carcinoid tumors and the carcinoid syndrome. CUff Probl Surg 1989; 26: 835–85.
   PubMed Web of Science ®Google Scholar
• Strodel WE, Talpos G, Eckhauser F, Thompson N. Surgical therapy for small-bowel carcinoid tumors. Arch Surg 1983; 118: 391–7.
   PubMedGoogle Scholar
• Rivadeneira DE, Tuckson WB, Naab T. Increased incidence of second primary malignancy in patients with carcinoid tumors: case report and literature review. J Natl Med Assoc 1996; 88: 310–2.
   Google Scholar
• Brown NK, Smith MR Neoplastic diathesis of patients with carcinoid. Report of a case with four other neoplasms. Cancer 1973; 32: 216–22.
   Google Scholar
• Jetmore AB, Ray JE, Gathright JBJ, McMullen KM, Hicks TC, Timmcke AE. Rectal carcinoids: The most frequent carcinoid tumor. Dis Colon Rectum 1992; 35: 717–25.
   PubMed Web of Science ®Google Scholar
• Dusmet ME, McKneally MF. Pulmonary and thymic carci-noid tumors. World J Surg 1996; 20: 189–95.
   PubMed Web of Science ®Google Scholar
• Harpole DHJ, Feldman JM, Buchanan S, Young WG, Wolfe WG. Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Ann Thorac Surg 1992; 54: 50–4 (discussion 54-5).
   Google Scholar
• Dusmet M, McKneally MF. Bronchial and thymic carcinoid tumors: a review Digestion 1994; 55(Suppl 3): 70–6.
   PubMed Web of Science ®Google Scholar
• Froudarakis M, Foumel P, Burgard G, et al. Bronchial carcinoids. A review of 22 cases. Oncology 1996; 53: 153–8.
   Google Scholar
• Limper AH, Carpenter PC, Scheithauer B, Staats BA. The Cushing syndrome induced by bronchial carcinoid tumors. Ann Intern Med 1992; 117: 209–14.
   PubMed Web of Science ®Google Scholar
• Wajchenberg B, Mendonca B, Liberman B, et al. Ectopic adrenocorticotropic hormone syndrome. Endocr Rev 1995; 15: 752–87.
   Web of Science ®Google Scholar
• Chughtai TS, Morin JE, Sheiner NM, Wilson JA, Mulder DS. Bronchial carcinoid-twenty years' experience defines a selective surgical approach. Surgery 1997; 122: 801–8.
   Google Scholar
• Shigeta H, Taga M, Kurogi K, Kitamura H, Motoyama T, Gorai I. Ovarian stromal carcinoid with severe constipation: immunohistochemical and mRNA analyses of peptide YY. Hum Pathol 1999; 30: 242–6.
   PubMed Web of Science ®Google Scholar
• Feyrter F. Ober diffuse endokrine epitheliale organe. Leipzig: J. A. Barth; 1938.
   Google Scholar
• Creutzfeldt W. Carcinoid tumors: development of our knowl-edge. World J Surg 1996; 20: 126–31.
   PubMed Web of Science ®Google Scholar
• Zeitels J, Naunheim K, Kaplan EL, Straus Fd. Carcinoid tumors: a 37-year experience. Arch Surg 1982; 117: 732–7.
   PubMedGoogle Scholar
• Pearse AGE. The cytochemistry and ultrastructure of poly-peptide hormone producing cells of the APUD series and the embyrologic, physiologic, and pathologic implications of the concept. J Histochem Cytochem 1969; 17: 303–13.
   PubMed Web of Science ®Google Scholar
• Creutzfeldt W Historical background and natural history of carcinoids. Digestion 1994; 55\(Suppl 3): 3–10.
   Google Scholar
• Kloppel G, Heitz P. Classification of normal and neoplastic neuroendocrine cells. Ann NY Acad Sci 1994; 733: 18–23.
   Web of Science ®Google Scholar
• Wilander E. Diagnostic pathology of gastrointestinal and pancreatic neuroendocrine tumors. Acta Oncol 1989; 28: 363–9.
   PubMed Web of Science ®Google Scholar
• Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumour. Lancet 1998; 352(9130): 799–805.
   PubMed Web of Science ®Google Scholar
• Bender DA. Biochemistry of tryptophan in health and disease. Mol Aspects Med 1983; 6: 101–97.
   PubMed Web of Science ®Google Scholar
• Siu LL, Chapman W, Moore MJ. Use of the somatostatin analogue octreotide acetate in the treatment of encephalo-pathy associated with carcinoid tumor. Case report. Am J Clin Oncol 1997; 20: 558–61.
   Google Scholar
• Norton JA. Surgical management of carcinoid tumors: role of debulking and surgery for patients with advanced disease. Digestion 1994; 55(Suppl 3): 98–103.
   PubMed Web of Science ®Google Scholar
• Vinik Al, Thompson N, Eckhauser F, Moattari AR. Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management. Acta Oncol 1989; 28: 389–402.
   PubMed Web of Science ®Google Scholar
• Davis Z, Moertel CG, McIlrath DC. The malignant carcinoid syndrome. JAM Coll Surg 1973; 137: 637–44.
   Google Scholar
• Grahame-Smith D. The carcinoid syndrome. London: Wil-liam Heineman Medical Books; 1972.
   Google Scholar
• Creutzfeldt W, Stockmann F. Carcinoids and carcinoid syndrome. Am J Med 1987; 82: 4–16.
   PubMed Web of Science ®Google Scholar
• Richter G, Stockmann F, Conlon JM, Creutzfeldt W Ser-otonin release into blood after food and pentagastrin. Studies in healthy subjects and in patients with metastatic carcinoid tumors. Gastroenterology 1986; 91: 612–8.
   Google Scholar
• Lucas KJ, Feldman JM. Flushing in the carcinoid syndrome and plasma kallikrein. Cancer 1986; 58: 2290–3.
   PubMed Web of Science ®Google Scholar
• Memon MA, Nelson H. Gastrointestinal carcinoid tumors: current management strategies. Dis Colon Rectum 1997; 40: 1101–18.
   PubMed Web of Science ®Google Scholar
• Vinik Al, McLeod MK, Fig LM, Shapiro B, Lloyd RV, Cho K. Clinical features, diagnosis, and localization of carcinoid tumors and their management. Gastroenterol Clin North Am 1989; 18: 865–96.
   PubMed Web of Science ®Google Scholar
• Peart W, Robertson JI. The effect of serotonin antagonist (UML 491) in carcinoid disease. Lancet 1961; 2: 1172–4.
   PubMed Web of Science ®Google Scholar
• Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993; 87: 1188–96.
   PubMed Web of Science ®Google Scholar
• Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echo-cardiography. Circulation 1995; 92: 790–5.
   Google Scholar
• Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine [published erratum appears in N Engl J Med 1997 Dec 11; 337: 1783]. N Engl J Med 1997; 337: 581–8.
   PubMed Web of Science ®Google Scholar
• Basson MD, Ahlman H, Wangberg B, Modlin IM. Biology and management of the midgut carcinoid. Am J Surg 1993; 165: 288–97.
   PubMed Web of Science ®Google Scholar
• Zirbes TK, Lorenzen J, Baldus SE, et al. Apoptosis and expression of bc1-2 protein are inverse factors influencing tumour cell turnover in primary carcinoid tumours of the lung. Histopathology 1998; 33: 123–8.
   PubMed Web of Science ®Google Scholar
• Przygodzki RM, Finkelstein SD, Langer JC, et al. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol 1996; 148: 1531–41.
   Google Scholar
• Dong Q, Debelenko LV, Chandrasekharappa SC, Emmert-Buck MR, Zhuang Z, Guru SC, et al. Loss of heterozygosity at 11q13: analysis of pituitary tumors, lung carcinoids, lipomas, and other uncommon tumors in subjects with familial multiple endocrine neoplasia type 1. J Clin Endocri-nol Metab 1997; 82(5): 1416–20.
   Google Scholar
• Debelenko LV, Brambilla E, Agarwal SK, et al. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet 1997; 6: 2285–90.
   PubMed Web of Science ®Google Scholar
• Brambilla E, Negoescu A, Gazzeri S, et al. Apoptosis-related factors p53, Bc12, and bax in neuroendocrine lung tumors. Am J Pathol 1996; 149: 1941–52.
   PubMed Web of Science ®Google Scholar
• Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med 1954; 16: 363–71.
   PubMed Web of Science ®Google Scholar
• Sagara M, Sugiyama F, Horiguchi H, et al. Activation of the nuclear oncogenes N-myc and c-jun in carcinoid tumors of transgenic mice carrying the human adenovirus type 12 El region gene. DNA Cell Biol 1995; 14: 95–101.
   PubMed Web of Science ®Google Scholar
• Cheng JY, Sheu LF, Meng CL, Lin JC. Expression of p53 protein in colorectal carcinoids. Arch Surg 1996; 131: 67–70.
   PubMedGoogle Scholar
• Coppola D, Clarke M, Landreneau R, Weyant RJ, Cooper D, Yousem SA. Bc1-2, p53, CD44, and CD44v6 isoform expres-sion in neuroendocrine tumors of the lung. Mod Pathol 1996; 9: 484–90.
   PubMed Web of Science ®Google Scholar
• Brandi ML, Marz SJ, Aurbach GD, Fitzpatrick LA. Familial multiple endocrine neoplasia type 1: A new look at patho-physiology. Endocr Rev 1987; 8: 391–405.
   PubMed Web of Science ®Google Scholar
• Jakobovitz O, Devora N, DeMarco L, et al. Carcinoid tumors frequently display genetic abnormalities involving chromo-some 11. J Clin Endocrinol Metab 1996; 81: 3164–7.
   PubMed Web of Science ®Google Scholar
• Bysrom C, Larsson C, Blomberg C, et al. Localization of the gene for multiple endocrine neoplasia type 1 to a small region within chromosome 11q13 by deletion mapping in tumor tissue. Proc Natl Acad Sci USA 1990; 87: 1968–72.
   PubMed Web of Science ®Google Scholar
• Friedman E, Sakaguchi K, Bale A. Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1. N Engl J Med 1989; 321: 213–8.
   Google Scholar
• Friedman E, DeMarco L, Gejman P. Allelic loss from chromosome 11 in parathyroid tumors. Cancer Res 1989; 52: 6804–9.
   Google Scholar
• Walch AK, Zitzelsberger HF, Aubele MM, et al. Typical and atypical carcinoid tumors of the lung are characterized by 1 lq deletions as detected by comparative genomic hybridization. Am J Pathol 1998; 153: 1089–98.
   PubMed Web of Science ®Google Scholar
• Perkins P, Lee JR, Kemp BL, Cox JD. Carcinoid tumors of the lung and family history of cancer. J Clin Epidemiol 1997; 50: 705–9.
   PubMed Web of Science ®Google Scholar
• Kovatich A, Friedland DM, Druck T, et al. Molecular alterations to human chromosome 3p loci in neuroendocrine lung tumors. Cancer 1998; 83: 1109–17.
   PubMed Web of Science ®Google Scholar
• Onuki N, Wistuba I, Travis WD, et al. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 1999; 85: 600–7.
   PubMed Web of Science ®Google Scholar
• Azzoni C, Doglioni C, Viale G, et al. Involvement of BCL-2 oncoprotein in the development of enterochromaffin like cell gastric carcinoids. Am J Surg Pathol 1996; 20: 433–41.
   PubMed Web of Science ®Google Scholar
• Rindi G. Characterisation of neuroendocrine tumors in transgenic mice. Digestion 1994; 55: 24–30.
   PubMed Web of Science ®Google Scholar
• Modlin IM, Lawton GP, Tang LH, Geibel J, Abraham R, Darr U. The Mastomys gastric carcinoid: aspects of enter-ochromaffin-like cell function. Digestion 1994; 55(Suppl 3): 31–7.
   PubMed Web of Science ®Google Scholar
• Nilsson O, Bilchik AI Adrian TE, Modlin IM. Intra-ocular transplantation of carcinoid tumours from Mastomys and humans. J Pathol 1990; 160: 347–56.
   PubMed Web of Science ®Google Scholar
• Suyama M, Saito T, Hara K, Kito H, Hosoda S. Production of serotonin by a transplantable strain of histamine producing primary gastric carcinoid of Mastomys natalensis. J Natl Cancer Inst 1984; 72: 751–7.
   Google Scholar
• Chaudhry A, Funa K, Oberg K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol 1993; 32: 107–14.
   Google Scholar
• Beauchamp RD, Coffey Jr. RI Lyons RM, Perkett EA, Townsend Jr. CM, Moses HL. Human carcinoid cell produc-tion of paracrine growth factors that can stimulate fibroblast and endothelial cell growth. Cancer Res 1991; 51: 5253–60.
   Google Scholar
• Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tu-mours. Histopathology 1998; 32: 133–8.
   PubMed Web of Science ®Google Scholar
• Ambs S, Bennett WP, Merriam WG, et al. Vascular endothe-lial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer 1998; 78: 233–9.
   PubMed Web of Science ®Google Scholar
• Chaudhry A, Oberg K, Gobl A, Heldin CH, Funa K. Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. Anticancer Res 1994; 14: 2085–91.
   Google Scholar
• Nilsson O, Wangberg B, Kolby L, Schultz GS, Ahlman H. Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours. Int J Cancer 1995; 60: 645–51.
   Google Scholar
• Krishnamurthy S, Dayal Y. Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in gastrointestinal carcinoids. Am J Surg Pathol 1997; 21: 327–33.
   PubMed Web of Science ®Google Scholar
• Facco C, La Rosa S, Dionigi A, Uccella S, Riva C, Capella C. High expression of growth factors and growth factor receptors in ovarian metastases from ileal carcinoids: an immunohisto-chemical study of 2 cases. Arch Pathol Lab Med 1998; 122: 828–32.
   PubMed Web of Science ®Google Scholar
• Nilsson O, Wangberg B, McRae A, Dahlstrom A, Ahlman H. Growth factors and carcinoid tumours. Acta Oncol 1993; 32: 115–24.
   Google Scholar
• Funa K, Papanicolaou V, Juhlin C, et al. Expression of platelet-derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors. Cancer Res 1990; 50: 748–53.
   PubMed Web of Science ®Google Scholar
• Williams E, Sanders M. The classification of carcinoid tumors. Lancet 1963; 1: 238–9.
   PubMed Web of Science ®Google Scholar
• Zeiger MA, Swartz SE, MacGillivray DC, Linnoila I, Shakir M. Thymic carcinoid in association with MEN syndromes. Am Surg 1992; 58: 430–4.
   Google Scholar
• Burcharth F, Axelsson C. Lung carcinoids. Scand Cardiovasc J 1973; 7: 72–7.
   Google Scholar
• Goldman NC, Hood CI, Singleton GT. Carcinoid of the larynx. Arch Otolaryngol Head Neck Surg 1969; 90: 64–7.
   Google Scholar
• Robboy SJ. Insular carcinoid of ovary associated with malignant mucinous tumors. Cancer 1984; 54: 2273–6.
   PubMed Web of Science ®Google Scholar
• Yalla SV, Yalla SS, Morgan JW, Eberhart CA, O11ey JF. Primary argentaffinoma of the testis: a case report and survey of the literature. J Urol 1974; 111: 50–2.
   Google Scholar
• Sylora HO, Diamond HM, Kaufman M, Straus FD, Lyon ES. Primary carcinoid tumor of the urethra. J Urol 1975; 114: 150–3.
   Google Scholar
• Hughes JP, Ancalmo N, Leonard GL, Ochsner JL. Carcinoid tumour of the thymus gland: report of a case. Thorax 1975; 30: 470–5.
   PubMed Web of Science ®Google Scholar
• Porter JM, Kalloo AN, Abernathy EC, Yeo CJ. Carcinoid tumor of the gallbladder: laparoscopic resection and review of the literature. Surgery 1992; 112: 100–5.
   PubMed Web of Science ®Google Scholar
• Kloppel G, Heitz PU, Capella C, Solcia E. Pathology and nomenclature of human gastrointestinal neuroendocrine (car-cinoid) tumors and related lesions. World J Surg 1996; 20: 132–41.
   PubMed Web of Science ®Google Scholar
• Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Digestion 1994; 55(Suppl 3): 11–23.
   Google Scholar
• Soga J, Tazawa K. Pathologic analysis of carcinoids. Histo-logic reevaluation of 62 cases. Cancer 1971; 28: 990–8.
   Google Scholar
• Soga J, Suzuki T. Carcinoids and the carcinoid syndrome. Nippon Rinsho 1993; 51 (Suppl): 207–21.
   Google Scholar
• Gosset A, Masson P. Tumeurs endocrine de l'appendice. Presse Med 1914; 22: 237.
   Google Scholar
• Martin RG. Management of carcinoid tumors. Cancer 1970; 26: 547–51.
   PubMed Web of Science ®Google Scholar
• Thompson GB, van Heerden JA, Martin Jr. JK, Schutt AI Ilstrup DM, Carney JA. Carcinoid tumors of the gastro-intestinal tract: presentation, management, and prognosis. Surgery 1985; 98: 1054–63.
   Google Scholar
• Tormey WP, FitzGerald RI The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid. Postgrad Med J 1995; 71: 542–5.
   PubMed Web of Science ®Google Scholar
• Feldman J, Lee E. Serotonin content of foods: effect on urinary excretion of 5-hydroxyindoleacetic acid. Am J Clin Nutr 1985; 42: 639–43.
   PubMed Web of Science ®Google Scholar
• Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secreto-granin I), chromogranin C (secretogranin II) and pancreast-atin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995; 144: 49–59.
   Google Scholar
• Eriksson B. Tumor markers for pancreatic endocrine tumors, including chromogranins, HCG-alpha and HCG-beta. In: Mignon M, Jensen R, eds. Endocrine tumors of the pancreas: recent advances in research and management. Basel: S Karger; 1995. p. 121.
   Google Scholar
• Eriksson B, Oberg K. Peptide hormones as tumor markers in neuroendocrine gastrointestinal tumors. Acta Oncol 1991; 30: 477–83.
   PubMed Web of Science ®Google Scholar
• Norheim I, Oberg K, Theodorsson-Norheim E, et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 1987; 206: 115–25.
   Google Scholar
• Maton P, Hodgson HJF. Textbook of gastroenterology. London: Bailliere-Tindall; 1984.
   Google Scholar
• Krenning EP, Kooij PPM, Bakker WH, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phel]-octreotide. Ann NY Acad Sci 1994; 733: 496–506.
   PubMed Web of Science ®Google Scholar
• Westlin JE, Janson ET, Arnberg H, Ahlstrom H, Oberg K, Nilsson S. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phel]-octreotide. Acta Oncol 1993; 32: 783–6.
   PubMed Web of Science ®Google Scholar
• Shi W, Johnston CF, Buchanan KD, et al. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scin-tigraphy (Octreoscan): a comparative study with CT and MR imaging. QJM 1998; 91: 295–301.
   PubMed Web of Science ®Google Scholar
• Eriksson B, Bergstrom M, Lilja A, Ahlstrom H, Langstrom B, Oberg K. Positron emission tomography (PET) in neuro-endocrine gastrointestinal tumors. Acta Oncol 1993; 32: 189–96.
   PubMed Web of Science ®Google Scholar
• Rege SD, Hoh CK, Glaspy JA, et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 1993; 72: 82–90.
   PubMed Web of Science ®Google Scholar
• Warburg O. The metabolism of tumors. New York: Smoth; 1931.
   Google Scholar
• Weber G. Differential carbohydrate metabolism in tumor and host. In: Arnott M, Van Eys J, Wang J, eds. Molecular interrelations of nutrition and cancer. New York: Raven Press; 1981. p. 167–81.
   Google Scholar
• Jadvar H, Segall GM. False-negative fluorine-18-FDG PET in metastatic carcinoid. J Nucl Med 1997; 38: 1382–3.
   PubMed Web of Science ®Google Scholar
• Eriksson B, Bergstrom M, Sundin A, et al. The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci 2002; 970: 159–69.
   PubMed Web of Science ®Google Scholar
• Adams S, Baum RP, Hertel A, Schumm-Drager PM, Usadel KH, Hor G. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen. Nucl Med Commun 1998; 19: 641–7.
   Google Scholar
• Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendo-crine tumours. Eur Nucl Med 1998; 25(1): 79–83.
   Google Scholar
• Hanson MW, Feldman JM, Blinder RA, Moore JO, Coleman RE. Carcinoid tumors: Iodine-131 MIBG scintigraphy. Radi-ology 1989; 172: 699–703.
   Google Scholar
• Anthony LB, Martin W, Delbeke D, Sandler M. Somatostatin receptor imaging: predictive and prognostic considerations. Digestion 1996; 57(Suppl 1): 50–3.
   PubMed Web of Science ®Google Scholar
• Loftus JP, van Heerden JA. Surgical management of gastro-intestinal carcinoid tumors. Adv Surg 1995; 28: 317–36.
   PubMedGoogle Scholar
• Rothmund M, Kisker O. Surgical treatment of carcinoid tumors of the small bowel, appendix, colon and rectum. Digestion 1994; 55(Suppl 3): 86–91.
   PubMed Web of Science ®Google Scholar
• Stinner B, Kisker O, Zielke A, Rothmund M. Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum. World J Surg 1996; 20: 183–8.
   PubMed Web of Science ®Google Scholar
• Marty-Ane CH, Costes V, Pujol JL, Alauzen M, Baldet P, Mary H. Carcinoid tumors of the lung: do atypical features require aggressive management? Ann Thorac Surg 1995; 59: 78–83.
   Google Scholar
• Okike N, Bernatz PE, Payne WS, Woolner LB, Leonard PF. Bronchoplastic procedures in the treatment of carcinoid tumors of the tracheobronchial tree. J Thorac Cardiovasc Surg 1978; 76: 281–91.
   PubMed Web of Science ®Google Scholar
• Vadasz P, Palffy G, Egervary M, Schaff Z. Diagnosis and treatment of bronchial carcinoid tumors: clinical and patho-logical review of 120 operated patients. Eur J Cardiothorac Surg 1993; 7: 8–11.
   PubMed Web of Science ®Google Scholar
• Fraser RG, Pare J, Pare PD, Fraser RS, Genereux GE Neoplastic diseases of the lungs (neoplasms of pulmonary neuroendocrine cells). In: Fraser RG, ed. Diagnosis of diseases of the chest, 3rd ed. Philadelphia: W.B. Saunders; 1989. p. 1476–94.
   Google Scholar
• Peplinski GR, Norton JA. Gastrointestinal endocrine cancers and nodal metastasis: Biologic significance and therapeutic implications. Surg Oncol Clin North Am 1996; 5: 159–71.
   PubMedGoogle Scholar
• Stuart RC. Primary gastric carcinoids. Br J Surg 1991; 78: 122–3.
   PubMed Web of Science ®Google Scholar
• Davies MG, O'Dowd G, McEntee GP, Hennessy TP. Primary gastric carcinoids: a view on management. Br J Surg 1990; 77: 1013–4.
   PubMed Web of Science ®Google Scholar
• Akerstrom G, Makridis C, Johansson H. Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol 1991; 30: 547–53.
   Google Scholar
• Moertel CG, Weiland LH, Nagorney DM, Dockerty MB. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med 1987; 317: 1699–701.
   PubMed Web of Science ®Google Scholar
• Reichlin S. Somatostatin. N Engl J Med 1983; 309: 1495–501.
   Google Scholar
• Reichlin S. Somatostatin. Part II. N Engl J Med 1983; 309: 1556–63.
   Google Scholar
• Lamberts S, Krenning E, Reubi J. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991; 12: 450–82.
   Google Scholar
• Bruns C, Weckbecker G, Raulf F, et al. Molecular pharma-cology of somatostatin-receptor subtypes. Ann N Y Acad Sci 1994; 733: 138–46.
   PubMed Web of Science ®Google Scholar
• Lambert P, Minghini A, Pincus W, Kolm P, Perry RR. Treatment and prognosis of primary malignant small bowel tumors. Am Surg 1996; 62: 709–15.
   Google Scholar
• Lamberts S, Uitterlinden P, Verschoor L, van Dongen K, del Pozo E. Long term treatment of acromegaly with the somatosatin analogue SMS201-995. N Engl J Med 1985; 313: 1576–80.
   Google Scholar
• Schally A. Oncological applications of somatostatin analogue. Cancer Res 1988; 48: 6977–85.
   PubMed Web of Science ®Google Scholar
• Hillman N, Herranz L, Alvarez C, Martinez Olmos MA, Marco A, Gomez-Pan A. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan). Exp Clin Endocrinol Diabetes 1998; 106: 226–30.
   Google Scholar
• Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315: 663–6.
   Google Scholar
• Oberg K. Treatment of neuroendocrine tumors. Cancer Treat Rev 1994; 20: 331–55.
   PubMed Web of Science ®Google Scholar
• Frolich JC, Bloomgarden ZT, Oates JA, McGuigan JE, Rabinowitz D. The carcinoid flush. Provocation by pentagas-trin and inhibition by somatostatin. N Engl J Med 1978; 299: 1055–7.
   Google Scholar
• Dharmsathaphorn K, Sherwin RS, Cataland S, Jaffe B, Dobbins J. Somatostatin inhibits diarrhea in the carcinoid syndrome. Ann Intern Med 1980; 92: 68–9.
   Google Scholar
• Vinik A, Moattari AR. Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci 1989; 34\(Suppl 3): 14S–27.
   Google Scholar
• Oberg K, Norheim I, Theodorsson E. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol 1991; 30: 503–7.
   Google Scholar
• Wangberg B, Nilsson O, Theodorsson E, Dahlstrom A, Ahlman H. The effect of a somatostatin analogue on the release of hormones from human midgut carcinoid tumour cells. Br J Cancer 1991; 64: 23–8.
   Google Scholar
• Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastro-enterol 1998; 93: 1468–71.
   PubMed Web of Science ®Google Scholar
• Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 17: 600–6.
   PubMed Web of Science ®Google Scholar
• Kvols L, Moertel C, Schutt A, Rubin J. Treatment of the malignant carcinoid syndrome with a long-acting somatosta-tin analogue (SMS 201-955): preliminary evidence that more is not better (abstract). Proc Am Soc Clin Oncol 1987; 6: 95.
   Google Scholar
• Saltz L, Trochanowski B, Buckley M, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993; 72: 244–8.
   PubMed Web of Science ®Google Scholar
• Janson EM, Ahlstrom H, Andersson T, Oberg KE. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 1992; 10: 1647–50.
   Web of Science ®Google Scholar
• Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combina-tion with alpha-interferon. Acta Oncol 1993; 32: 225–9.
   Google Scholar
• Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996; 38: 430–8.
   PubMed Web of Science ®Google Scholar
• Creutzfeldt W, Bartsch HH, Jacubaschke U, Stockmann F. Treatment of gastrointestinal endocrine tumours with inter-feron-alpha and octreotide. Acta Oncol 1991; 30: 529–35.
   PubMed Web of Science ®Google Scholar
• Hanssen LE, Schrumpf E, Kolbenstvedt AN, Tausjo J, Dolva LO. Treatment of malignant metastatic midgut carcinoid tumours with recombinant human alpha2b interferon with or without prior hepatic artery embolization. Scand J Gastroenterol 1989; 24: 787–95.
   Google Scholar
• Oberg K. Chemotherapy and biotherapy in neuroendocrine tumors. Curr Opin Oncol 1993; 5: 110–20.
   PubMedGoogle Scholar
• Valimaki M, Jarvinen H, Salmela P, Sane T, Sjoblom SM, Pelkonen R. Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer 1991; 67: 547–9.
   PubMed Web of Science ®Google Scholar
• Oberg K, Norheim I, Lind E, et al. Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results. Cancer Treat Rep 1986; 70: 1297–304.
   PubMedGoogle Scholar
• Nobin A, Lindblom A, Mansson B, Sundberg M. Interferon treatment in patients with malignant carcinoids. Acta Oncol 1989; 28: 445–9.
   PubMed Web of Science ®Google Scholar
• Oberg K, Norheim I, Alm G. Treatment of malignant carcinoid tumors: a randomized controlled study of strepto-zocin plus 5-FU and human leukocyte interferon. Eur J Cancer Clin Oncol 1989; 25: 1475–9.
   Google Scholar
• Oberg K, Eriksson B, Janson ET. The clinical use of interferons in the management of neuroendocrine gastroen-teropancreatic tumors. Ann N Y Acad Sci 1994; 733: 471–8.
   Google Scholar
• Moertel CG, Rubin J, Kvols LK. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 1989; 7: 865–8.
   Google Scholar
• Oberg K, Alm G, Magnusson A, et al. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: devel-opment of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst 1989; 81: 531–5.
   PubMed Web of Science ®Google Scholar
• Bartsch HH, Stockmann F, Arnold R, Creutzfeldt W Treat-ment of patients with metastatic carcinoid tumors by recom-binant human interferon-alpha-results from a phase II study (abstract). J Cancer Res Clin Oncol 1990; 116 (Suppl): 305.
   Google Scholar
• Oberg K, Eriksson B. The role of interferons in the manage-ment of carcinoid tumors. Acta Oncol 1991; 30: 519–22.
   PubMed Web of Science ®Google Scholar
• Schober C, Schmoll E, Schmoll HJ, et al. Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours. Eur J Cancer 1992; 10: 1664–6.
   Web of Science ®Google Scholar
• Joensuu H, Kumpulainen E, Grohn P. Treatment of metastatic carcinoid tumour with recombinant interferon alfa. Eur J Cancer 1992; 10: 1650–3.
   Google Scholar
• Janson ET, Ronnblom L, Ahlstrom H, et al. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol 1992; 3: 635–8.
   PubMed Web of Science ®Google Scholar
• Bajetta E, Zilembo N, Di Bartolomeo M, et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. Cancer 1993; 72: 3099–105.
   Google Scholar
• Di Bartolomeo M, Bajetta E, Zilembo N, et al. Treatment of carcinoid syndrome with recombinant interferon alpha-2a [published erratum appears in Acta Oncol 1993; 32: 592]. Acta Oncol 1993; 32: 235–8.
   PubMed Web of Science ®Google Scholar
• Jacobsen MB, Hanssen LE, Kolmannskog F, Schrumpf E, Vatn MH, Bergan A. Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carci-noid study. Scand J Gastroenterol 1995; 30: 789–96.
   PubMed Web of Science ®Google Scholar
• Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999; 94: 1381–7.
   Google Scholar
• Stathopoulos GP, Karvountzis GG, Yiotis J. Tamoxifen in carcinoid syndrome. N Engl J Med 1981; 305: 52.
   PubMed Web of Science ®Google Scholar
• Myers CF, Ershler WB, Tannenbaum MA, Barth R. Tamox-ifen and carcinoid tumor. Ann Intern Med 1982; 96: 383.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Engstrom PF, Schutt AJ. Tamoxifen therapy for metastatic carcinoid tumor: a negative study. Ann Intern Med 1984; 100: 531–2.
   Google Scholar
• Moertel CG, Martin JK, O'Connell MJ, et al. Phase II trials in the malignant carcinoid tumor and the carcinoid syndrome. Proc Am Soc Clin Oncol 1982; 2: 169.
   Google Scholar
• Engstrom PF, Lavin PT, Moertel CG, Folsch E, Douglass Jr. HO. Streptozocin plus fluorouracil versus doxorubicin ther-apy for metastatic carcinoid tumor. J Clin Oncol 1984; 2: 1255–9.
   Google Scholar
• Oberg K, Norheim I, Lundqvist G, Wide L. Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin-alone or in combination with 5-FU. Acta Oncol 1987; 26: 429–32.
   Google Scholar
• Saltz L, Kemeny N, Schwartz G, Kelsen D. A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer 1994; 74: 958–61.
   PubMed Web of Science ®Google Scholar
• Ajani J, Humberto C, Wallace S. Neuroendocrine tumors metastatic to the liver: vascular occlusion therapy. Ann N Y Acad Sci 1994; 733: 479–87.
   Google Scholar
• Nobin A, Mansson B, Lunderquist A. Evaluation of tempor-ary liver dearterialization and embolization in patients with metastatic carcinoid tumour. Acta Oncol 1989; 28: 419–24.
   Google Scholar
• Chuang VP, Soo CS, Carrasco CH, et al. Superselective catheterization technique in hepatic angiography. Am J Radiol 1983; 141: 803–11.
   Google Scholar
• Diaco DS, Hajarizadeh H, Mueller CR, Fletcher WS, Pommier RF, Woltering EA. Treatment of metastatic carci-noid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization. Am J Surg 1995; 169: 523–8.
   PubMed Web of Science ®Google Scholar
• Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol 1986; 147: 149–54.
   PubMed Web of Science ®Google Scholar
• Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE, Oberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Can-cer 1998; 83: 2293–301.
   Google Scholar
• Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endo-crine tumors. A prospective phase II study in 24 patients. Cancer 1993; 71: 2624–30.
   Google Scholar
• Therasse E, Breittmayer F, Roche A, et al. Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 1993; 189: 541–7.
   PubMed Web of Science ®Google Scholar
• Perry LJ, Stuart K, Stokes KR, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 1994; 116: 1111–6 (discussion 1116-7).
   PubMed Web of Science ®Google Scholar
• Drougas JG, Anthony LB, Blair TK, et al. Hepatic artery chemoembolization for management of patients with ad-vanced metastatic carcinoid tumors. Am J Surg 1998; 175: 408–12.
   PubMed Web of Science ®Google Scholar
• Diamandidou E, Ajani JA, Yang DJ, et al. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR Am J Roentgenol 1998; 170: 339–44.
   PubMed Web of Science ®Google Scholar
• Kim YH, Ajani JA, Carrasco CH, et al. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest 1999; 17: 474–8.
   PubMed Web of Science ®Google Scholar
• Schupak KD, Wallner KE. The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors. Int J Radiat Oncol Biol Phys 1991; 20: 489–95.
   PubMed Web of Science ®Google Scholar
• Kimmig BN. Radiotherapy for gastroenteropancreatic neuroendocrine tumors. Ann N Y Acad Sci 1994; 733: 488–95.
   PubMed Web of Science ®Google Scholar
• Otte A, Mueller-Brand J, Dellas S, Nitzsche E, Herrmann R, Maecke H. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998; 351: 417–8.
   PubMed Web of Science ®Google Scholar
• Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H, Beijnen JH. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 1996; 14: 1829–38.
   Google Scholar
• Modlin IM, Cornelius EA, Zoghbi SS, et al. Phase I-II trial of radiolabeled pentetreotide therapy. [Abstract]. Proc Am Soci Clin Oncol 1999; 18: 186a.
   Google Scholar
• Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995; 169: 36–42 (discussion 42-43).
   Google Scholar
• Frilling A, Rogiers X, Malago M, Liedke O, Kaun M, Broelsch CE. Liver transplantation in patients with liver metastases of neuroendocrine tumors. Transplant Proc 1998; 30: 3298–300.
   PubMed Web of Science ®Google Scholar
• Bechstein W, Neuhaus P. Liver transplantation for hepatic metastases of neuroendocrine tumors. Ann N Y Acad Sci 1994; 733: 507–14.
   PubMed Web of Science ®Google Scholar
• Le Treut YP, Delpero JR, Dousset B, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg 1997; 225: 355–64.
   PubMed Web of Science ®Google Scholar
• Kvols LK. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Ann N Y Acad Sci 1994; 733: 464–70.
   PubMed Web of Science ®Google Scholar
• Aranha GV, Greenlee HB. Surgical management of carcinoid tumors of the gastrointestinal tract. Am Surg 1980; 46: 429–35.
   PubMed Web of Science ®Google Scholar
• Syracuse DC, Perzin KH, Price JB, Wiedel PD, Mesa-Tejada R. Carcinoid tumors of the appendix. Mesoappendiceal extension and nodal metastases. Ann Surg 1979; 190: 58–63.
   Google Scholar
• McDermott EW, Guduric B, Brennan ME Prognostic vari-ables in patients with gastrointestinal carcinoid tumours. Br J Surg 1994; 81: 1007–9.
   PubMed Web of Science ®Google Scholar
• Ruebi J, Laissue J, Waser B, Horisberger U, Schaer J. Expression of somatostatin receptors in normal inflammed and neoplastic human gastrointestinal tissues. Ann N Y Acad Sci 1994; 733: 122–37.
   Google Scholar
• Eller R, Frazee R, Roberts J. Gastrointestinal carcinoid tumors. Am Surg 1991; 57: 434–7.
   Google Scholar
• Haq AU, Yook CR, Hiremath V, Kasimis BS. Carcinoid syndrome in the absence of liver metastasis: a case report and review of literature. Med Pediatr Oncol 1992; 20: 221–3.
   PubMedGoogle Scholar
• Grahame-Smith DG. The carcinoid syndrome. Am J Cardiol 1968; 21: 376–87.
   PubMed Web of Science ®Google Scholar
• Kirshbom PM, Kherani AR, Onaitis MW, Feldman JM, Tyler DS. Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids. Surgery 1998; 124: 1063–70.
   Google Scholar
• McBride LC, Righi PD, Krakovitz PR. Case study of well-differentiated carcinoid tumor of the larynx and review of laryngeal neuroendocrine tumors. Otolaryngol Head Neck Surg 1999; 120: 536–9.
   Google Scholar
• Krishnamurthy SC, Dutta V, Pai SA, et al. Primary carcinoid tumor of the liver: report of four resected cases including one with gastrin production. J Surg Oncol 1996; 62: 218–21.
   PubMed Web of Science ®Google Scholar
• Makridis C, Oberg K, Juhlin C, et al. Surgical treatment of mid-gut carcinoid tumors. World J Surg 1990; 14: 377–83 (discussion 384-5).
   PubMed Web of Science ®Google Scholar
• Creutzfeld C, Track NS, Creutzfledt W In vitro studies of the rate of proinsulin and insulin turnover in seven human insulinomas. Eur J Clin Invest 1973; 3: 371–84.
   PubMed Web of Science ®Google Scholar
• Janmohamed S, Bloom SR. Carcinoid tumours. Postgrad Med J 1997; 73(858): 207–14.
   PubMed Web of Science ®Google Scholar
• Kema IP, de Vries EG, Slooff MJ, Biesma B, Muskiet FA. Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors. Clin Chem 1994; 40: 86–95.
   PubMed Web of Science ®Google Scholar
• Janson ET, Kauppinen HL, Oberg K. Combined alpha- and gamma-interferon therapy for malignant midgut carcinoid tumors. A phase I-II trial. Acta Oncol 1993; 32: 231–3.
   Google Scholar
• van Hazel GA, Rubin J, Moertel CG. Treatment of metastatic carcinoid tumor with dactinomycin or dacarbazine. Cancer Treat Rep 1983; 67: 583–5.
   Google Scholar
• Bukowski RM, Tangen CM, Peterson RF, Taylor SA, Rinehart JJ, Eyre HJ, et al. Phase II trial of dimethyltriaze-noimidazole carboxamide in patients with metastatic carci-noid. A Southwest Oncology Group study. Cancer 1994; 73: 1505–8.
   Google Scholar
• Ritzel U, Leonhardt U, Stockmann F, Ramadori G. Treat-ment of metastasized midgut carcinoids with dacarbazine. Am J Gastroenterol 1995; 90: 627–31.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Rubin J, O'Connell MJ. Phase II study of cisplatin therapy in patients with metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Treat Rep 1986; 70: 1459–60.
   Google Scholar
• Saltz L, Lauwers G, Wiseberg J, Kelsen D. A phase II trial of carboplatin in patients with advanced APUD tumors. Cancer 1993; 72: 619–22.
   PubMed Web of Science ®Google Scholar
• Kelsen D, Fiore J, Heelan R, Cheng E, Magill G. Phase II trial of etoposide in APUD tumors. Cancer Treat Rep 1987; 71: 305–7.
   PubMedGoogle Scholar
• Kulke MH, Fuchs CS, Stuart K, Ryan DP, Enziger PC, Vincitore M, et al. Phase II study of docetaxel in patients with metastatic carcinoid tumors. [Abstract]. Proc Am Soc Clin Oncol 2000; 19: 312a.
   Google Scholar
• Ajani J, Legha S, Karlin J, et al. Combination chemotherapy of metastatic carcinoid tumors with 5-FU, adriamycin, and cytoxan and 5-FU, adriamycin, mitomycin, and methyl CCNU. Proc Am Assoc Cancer Research 1983; 2: 124.
   Google Scholar
• Bukowski RM, Johnson KG, Peterson RF, et al. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer 1987; 60: 2891–5.
   Google Scholar
• Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227–32.
   Google Scholar
• Rougier P, Oliveira J, Ducreux M, Theodore C, Kac J, Droz JP. Metastatic carcinoid and islet cell tumours of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin. Eur J Cancer 1991; 27: 1380–2.
   PubMed Web of Science ®Google Scholar
• Di Bartolomeo M, Bajetta E, Bochicchio AM, et al. A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.0.) Group. Ann Oncol 1995; 6: 77–9.
   PubMed Web of Science ®Google Scholar
• O11ivier S, Fonck M, Becouarn Y, Brunet R. Dacarbazine, fluorouracil, and leucovorin in patients with advanced neu-roendocrine tumors: a phase II trial. Am J Clin Oncol 1998; 21: 237–40.
   Google Scholar
• Maton PN, Camilleri M, Griffin G, Allison DJ, Hodgson HJ, Chadwick VS. Role of hepatic arterial embolisation in the carcinoid syndrome. Br Med J 1983; 287: 932–5.
   PubMed Web of Science ®Google Scholar